Table 2.
Clinical and Genetic Features From Patients Carrying Rare TRPM4 Variants
Patients | TRPM4 Variants | Variant Frequency in ExAc (Controls) | ||||||
---|---|---|---|---|---|---|---|---|
No. | Age and Rhythm at Diagnosis | Age and Rhythm at Implantation | Exon | Nucleotide | Amino Acid | European | ||
1 | 10.5 years | Complete AVB | 13 years | Complete AVB | 05 | c.593A>G | p.Asp198Gly | 0 |
2 | 6 months |
AVB1 AVB2 Type 1 |
9 years | Complete AVB | 06 | c.755G>A | p.Arg252His | 0.0082 |
3a | 5 years | Complete AVB | 11 years | Complete AVB |
11 13 |
c.1294G>A c.1744G>A |
p.Ala432Thr p.Gly582Ser |
0.0005 0.0006 |
4a | 7 years | First‐degree AVB | No pacemaker | — |
11 13 |
c.1294G>A c.1744G>A |
p.Ala432Thr p.Gly582Ser |
0.0005 0.0006 |
5 | 6 years | Complete AVB | 9 years | Complete AVB | 11 | c.1458_1493del36 | p.Lys487_Leu498del | 0 |
6 | 4 months | Complete AVB | 5 months | Complete AVB | 15 | c.2030C>T | p.Thr677Ile | 0 |
7 |
In utero 33 weeks of gestation |
Complete AVB | 3 days | Complete AVB | 16 | c.2209G>A | p.Gly737Arg | 0.0017 |
8 |
In utero 36 weeks of gestation |
Complete AVB | 1 day | Complete AVB | 17 | c.2531G>A | p.Gly844Asp | 0.0044 |
9 | At birth | Complete AVB | 3 days | Complete AVB | 17 | c.2531G>A | p.Gly844Asp | 0.0044 |
10 | 8.5 years | Complete AVB | 8.5 years | Complete AVB | 17 | c.2531G>A | p.Gly844Asp | 0.0044 |
11 | At birth | Complete AVB | 2 days | Complete AVB | 17 | c.2531G>A | p.Gly844Asp | 0.0044 |
12 |
In utero 38 weeks of gestation |
Complete AVB | 1 day | Complete AVB | 17 | c.2531G>A | p.Gly844Asp | 0.0044 |
13 | 18 months |
AVB1 AVB 2/1 |
2 years | Complete AVB | 18 | c.2761G>A | p.Val921Ile | 0.0001 |
14 | 5 years | Complete AVB | 5.5 years | Complete AVB | 24 | c.3611C>T | p.Pro1204Leu | 0.0051 |
TRPM4 genotypes and their respective allele frequencies in controls are presented for 14 congenital AVB cases. Age and rhythm at diagnosis and pacemaker implantation are presented for each patient. (1) c.355G>T, p.A119S. (2) c.5415_5418del415 p.Thr1806SerfsX27. AVB indicates atrioventricular block; ExAc, Exome Aggregation Consortium.
Patients 3 and 4 also harbor NKX2.5 and SCN5A point mutations, respectively.